|
KMID : 0982820100090010015
|
|
Journal of Lung Cancer
2010 Volume.9 No. 1 p.15 ~ p.19
|
|
|
Belotecan and Cisplatin Combination Chemotherapy for Previously Untreated Extensive-Disease Small Cell Lung Cancer
|
|
Lee Jung-Eun
Lee Kye-Young
Park Hee-Sun
Kim Ju-Ock
Kim Sun-Young
Jung Sung-Soo
|
|
|
Abstract
|
|
|
Purpose: Belotecan (Camtobell?; Chong Keun Dang Co., Seoul, Korea) is a new camptothecin analog that inhibits topoisomerase I. We evaluated the efficacy and toxicity of belotecan combined with cisplatin in patients with previously untreated extensive-disease small cell lung cancer (ED-SCLC) and who were without evidence of brain metastases.
Materials and Methods: Twenty patients with previously untreated ED-SCLC were treated with belotecan (0.5 mg/m2/day) on days 1∼4 and with cisplatin (60 mg/m2/day) on day 1 of a 3-week cycle.
Results: Of the 19 assessable patients, 16 had an objective tumor response, including two complete responses, for an overall response rate of 84.2%. Toxicity was evaluated in all 20 patients who received a total of 106 cycles (median cycles/patient, 5.5; range, 1∼9). The major grade 3/4 hematologic toxicities were neutropenia (67.9% of cycles), anemia (19.8% of cycles) and thrombocytopenia (33.9% of cycles). No grade 3/4 non-hematologic toxicities were observed. No treatment-related deaths occurred. The median progression-free and overall survivals were 7.06 months (95% confidence interval [CI], 3.98∼10.14 months) and 9.96 months (95% CI, 6.12∼13.80 months), respectively.
Conclusion: Combination chemotherapy with belotecan plus cisplatin is an effective treatment for ED-SCLC with acceptable hematologic and non-hematologic toxicities
|
|
|
KEYWORD
|
|
|
Belotecan, Extensive disease, Small cell lung carcinoma, Cisplatin, First-line
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|